How It Works:
Human Papillomavirus (HPV) type 16 and 18 cause about 70% of cervical cancer. HPV bivalent (types 16 and 18) vaccine is a non-infectious vaccine produced by recombinant technology, which contains virus-like particles (VLP) of the major capsid L1 protein of oncogenic HPV types 16 and 18. Efficacy of vaccine may be mediated by the production of IgG neutralizing antibodies against the HPV-L1 capsid proteins.
Dizziness, Fever, Injection site redness, Injection site soreness, Itching, Nausea, Swelling
Human Papillomavirus Type 18 L1Protein is used to prevent pre cancerous anal lesions, pre cancerous genital lesions (cervical, vulvar and vaginal), cervical cancer, anal cancer and genital warts (skin bumps on or around the genital or anal area)